Expert Panel Reaches Consensus on Prostate Cancer Treatment Gaps
In Partnership With
Alan H. Bryce, MD, discusses areas of need to help guide treatment decisions in the clinic for prostate cancer management.
The 2024 US Prostate Cancer Conference (USPCC 2024) assembled in October to discuss areas of need to help guide treatment decisions in the clinic for prostate cancer management. In this video, Alan H. Bryce, MD, chief clinical officer and professor of Medical Oncology and Developmental Therapeutics at City of Hope in Phoenix, Arizona, provides an overview of these consensus recommendations.
Regarding the recommendation update, Bryce explains that “this is meant to be entirely practical. We were not there to debate esoteric research questions. We really were there to discuss the things that impact your clinic today, [speaking to the clinician].”
In the consensus recommendations, the expert panel identified 5 current areas of need in prostate cancer management. Each category outlines specific clinical scenarios and corresponding expert recommendations. These categories are as follows: biochemical recurrence, metastatic castration-sensitive prostate cancer, PARP inhibitors, prostate-specific membrane antigen radioligand therapy, and metastatic castration-resistant prostate cancer.
Bryce highlights that the goal of the USPCC 2024 conference was to identify those controversial questions and come together as experts to provide answers and clarity for these gray areas, following a strict Delphi process. The Delphi process is a widely recognized method for achieving expert consensus, involving multiple rounds of anonymous surveys where experts provide their input, followed by controlled feedback and discussion.
The conference is geared toward clinicians practicing in the US. Bryce explains that the “regulatory environment in the United States is entirely unique. No other country has access to all the drugs we have access to. Thus, no other community of physicians is facing the same types of questions that we face in the United States. This treatment guideline is specific for the American clinician in the American regulatory environment, with all the treatment options we have.”
Clinicians practicing in the US are encouraged to provide feedback on what topics they would like addressed in the upcoming USPCC 2025. Bryce explains that this enables the panel to address needs observed in the real world that level 1 evidence may not provide answers for.
